FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:313-315 July 20, 2006 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

A clear lesson that has emerged from growing experience with small-molecule kinase inhibitors is that a detailed knowledge of the drug target predicts clinical success in cancer treatment. Tumors with mutations that activate a kinase (or other proteins in the signaling pathway in which the kinase resides) are most likely to respond when they are treated with an appropriate inhibitor of that particular kinase.

Among the next wave of kinase inhibitors to be clinically tested are those designed to block Akt (also called protein kinase B), a molecule with all the hallmarks of a critical cancer target. The most compelling . . . [Full Text of this Article]

Source Information

From the Departments of Medicine, Molecular Pharmacology, and Urology, University of California, Los Angeles, Los Angeles.

This article has been cited by other articles:

• Le Cras, T. D., Korfhagen, T. R., Davidson, C., Schmidt, S., Fenchel, M., Ikegami, M., Whitsett, J. A., Hardie, W. D. (2010). Inhibition of PI3K by PX-866 Prevents Transforming Growth Factor-{alpha}-Induced Pulmonary Fibrosis. Am. J. Pathol. 176: 679-686 [Abstract] [Full Text]  
• Hardie, W. D., Glasser, S. W., Hagood, J. S. (2009). Emerging Concepts in the Pathogenesis of Lung Fibrosis. Am. J. Pathol. 175: 3-16 [Abstract] [Full Text]  
• Grothey, A. (2007). Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?. Clin. Cancer Res. 13: 6909s-6912s [Abstract] [Full Text]  
• Tamburini, J., Elie, C., Bardet, V., Chapuis, N., Park, S., Broet, P., Cornillet-Lefebvre, P., Lioure, B., Ugo, V., Blanchet, O., Ifrah, N., Witz, F., Dreyfus, F., Mayeux, P., Lacombe, C., Bouscary, D. (2007). Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110: 1025-1028 [Abstract] [Full Text]  
• Madhunapantula, S. V., Sharma, A., Robertson, G. P. (2007). PRAS40 Deregulates Apoptosis in Malignant Melanoma. Cancer Res. 67: 3626-3636 [Abstract] [Full Text]